SystImmune, Inc.

NEWS

Pictured: Bristol Myers Squibb in NJ/iStock, arlut

Business

BMS Inks Potential $8.4B Deal for SystImmune’s ADC for Lung, Breast Cancer

Bristol Myers Squibb has bought the rights to develop and commercialize SystImmune’s potentially first-in-class, bi-specific antibody-drug conjugate for lung and breast cancer as well as other solid tumors.

December 12, 2023

2 min read

Tristan Manalac

IN THE PRESS

Press Releases

SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M17D1 in Advanced Solid Tumors

November 8, 2024

3 min read

Press Releases

SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia

October 14, 2024

3 min read

Press Releases

SystImmune, Inc. to Present New BL-B01D1 Data in Urothelial, Biliary Tract, and Esophageal Squamous Cell Carcinoma at ESMO Congress 2024

September 9, 2024

5 min read

Business

SystImmune, Inc. Announces Transition of Chief Medical Officer

May 23, 2024

2 min read

Business

SystImmune, Inc. Appoints Dr. Jie D’Elia as Chief Executive Officer

April 22, 2024

2 min read

Business

SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1

December 11, 2023

8 min read

BioForest

SystImmune, Inc. Announces the Presentation of Breast Cancer Clinical Trial Results at the 2024 San Antonio Breast Cancer Conference and US Clinical Trial Developments

December 5, 2023

7 min read

BioForest

SystImmune, Inc. to Present New Oncology Pipeline Data at ESMO Congress 2023

October 20, 2023

5 min read

Drug Development

SystImmune, Inc. Announces First Patient Dosed in U.S. Phase 1 Clinical Trial of BL-B01D1 for the Treatment of Metastatic or Unresectable Non-Small Cell Lung Cancer

October 12, 2023

4 min read

BioForest

SystImmune, Inc. to Present New Data from Oncology Programs at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2023

May 1, 2023

7 min read

JOBS